Cargando…

Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment

Background. We examined (1) patient characteristics and disease-modifying drug (DMD) exposure in late-onset (LOMS, ≥50 years at symptom onset) versus adult-onset (AOMS, 18–<50 years) MS and (2) the association between interferon-beta (IFNβ) and disability progression in older relapsing-onset MS a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirani, Afsaneh, Zhao, Yinshan, Petkau, John, Gustafson, Paul, Karim, Mohammad Ehsanul, Evans, Charity, Kingwell, Elaine, van der Kop, Mia L., Oger, Joel, Tremlett, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397470/ https://www.ncbi.nlm.nih.gov/pubmed/25922836 http://dx.doi.org/10.1155/2015/451912

Ejemplares similares

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Evaluating the safety of β-interferons in MS: A series of nested case-control studies
por: de Jong, Hilda J.I., et al.
Publicado: (2017)

Sex and age differences in the Multiple Sclerosis prodrome
por: Yusuf, Fardowsa L. A., et al.
Publicado: (2022)

Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study
por: Zhang, Tingting, et al.
Publicado: (2017)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

The effect of smoking on the symptoms and progression of multiple sclerosis: a review
por: Shirani, Afsaneh, et al.
Publicado: (2010)

Disease-modifying drugs for multiple sclerosis and subsequent health service use
por: Ng, Huah Shin, et al.
Publicado: (2021)

Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study
por: Evans, Charity, et al.
Publicado: (2021)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

A multiple sclerosis disease progression measure based on cumulative disability
por: Manouchehrinia, Ali, et al.
Publicado: (2021)

A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada
por: McKay, Kyla, et al.
Publicado: (2017)

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
por: Graf, Jonas, et al.
Publicado: (2023)

Neonatal and Delivery Outcomes in Women with Multiple Sclerosis
por: van der Kop, Mia L, et al.
Publicado: (2011)

Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population
por: Ng, Huah Shin, et al.
Publicado: (2022)

Polypharmacy and multiple sclerosis: A population-based study
por: Chertcoff, Anibal, et al.
Publicado: (2022)

A longitudinal model for disease progression was developed and applied to multiple sclerosis
por: Lawton, Michael, et al.
Publicado: (2015)

Accurate classification of secondary progression in multiple sclerosis using a decision tree
por: Ramanujam, Ryan, et al.
Publicado: (2020)

UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
por: Palace, Jacqueline, et al.
Publicado: (2014)

Age Related Multiple Sclerosis Severity Score: Disability ranked by age
por: Manouchehrinia, Ali, et al.
Publicado: (2017)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis
por: Zhang, Tingting, et al.
Publicado: (2016)

Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits
por: Graf, Jonas, et al.
Publicado: (2022)

Personalized activity index, a new safety monitoring tool for multiple sclerosis clinical trials
por: Zhao, Yinshan, et al.
Publicado: (2015)

A population‐based study comparing multiple sclerosis clinic users and non‐users in British Columbia, Canada
por: McKay, K. A., et al.
Publicado: (2016)

Recommendations for the use of propensity score methods in multiple sclerosis research
por: Simoneau, Gabrielle, et al.
Publicado: (2022)

‘Beta-interferons’ and ‘oligoclonal bands’ in multiple sclerosis in India
por: Hassan, K. M.
Publicado: (2011)

Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study
por: McKay, Kyla A, et al.
Publicado: (2016)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
por: Jeannin, S., et al.
Publicado: (2011)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Malekzadeh, Masoud Mohammad, et al.
Publicado: (2020)

The Multiple Sclerosis Prodrome: Evidence to Action
por: Tremlett, Helen, et al.
Publicado: (2022)

High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010)
por: Kingwell, Elaine, et al.
Publicado: (2015)

The association between handedness and clinicodemographic characteristics in people with multiple sclerosis: a brief report
por: Shirani, Afsaneh, et al.
Publicado: (2019)

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
por: Furber, Kendra L, et al.
Publicado: (2017)

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
por: Simone, Isabella Laura, et al.
Publicado: (2006)

Beta-interferons in multiple sclerosis: A single center experience in India
por: Gupta, Salil, et al.
Publicado: (2010)

Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
por: Marziniak, Martin, et al.
Publicado: (2014)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop, Florian, et al.
Publicado: (2013)

PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
por: Reuss, Reinhard
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7h1665778khst1rjcn3s3jp0m0